Neha Krishnamohan
Known title: Chief Financial OfficerCIK: 0001866171
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.
Transaction History
| ARQT | ▲ Buy | Grant | 5,778 | $0 | 6/5/2026 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 3,490 | $11K | 11/15/2025 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 27,052 | $233K | 11/13/2025 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 12,220 | $92K | 11/13/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 39,272 | $911K | 11/13/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,232 | $29K | 11/13/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 5,813 | $16K | 8/15/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 7,609 | $0 | 6/12/2025 | View on chart |
| ARTV | ▼ Sell | Tax Withholding | 1,341 | $3K | 5/15/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 60,000 | $0 | 2/26/2025 | View on chart |
| ARTV | ▲ Buy | Grant | 50,000 | $0 | 9/12/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 10,139 | $0 | 6/14/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 4,375 | $0 | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.